Drug Nanoparticles: Formulating Poorly Water-Soluble Compounds
Tóm tắt
More than 40% of compounds identified through combinatorial screening programs are poorly soluble in water. These molecules are difficult to formulate using conventional approaches and are associated with innumerable formulation-related performance issues. Formulating these compounds as pure drug nanoparticles is one of the newer drug-delivery strategies applied to this class of molecules. Nanoparticle dispersions are stable and have a mean diameter of less than 1 micron. The formulations consist of water, drug, and one or more generally regarded as safe excipients. These liquid dispersions exhibit an acceptable shelf-life and can be postprocessed into various types of solid dosage forms. Drug nanoparticles have been shown to improve bioavailability and enhance drug exposure for oral and parenteral dosage forms. Suitable formulations for the most commonly used routes of administration can be identified with milligram quantities of drug substance, providing the discovery scientist with an alternate avenue for screening and identifying superior analogs. For the toxicologist, the approach provides a means for dose escalation using a formulation that is commercially viable. In the past few years, formulating poorly water-soluble compounds using a nanoparticulate approach has evolved from a conception to a realization whose versatility and applicability are just beginning to be realized.
Từ khóa
Tài liệu tham khảo
Bittner B, 2002, Curr Opin Drug Discovery Dev, 5, 59
Douglas SJ, 1987, Crit Rev Ther Drug Carrier Syst, 3, 233
FeynmanRP1959Plenty of room at the bottomCourtesy of the ArchivesCalifornia Institute of Technologywww.its.caltech.edu/~feynman/plenty.html
Liedtke S, 2000, Int J Pharm, 160, 229
Lipinski C, 2002, Am Pharm Rev, 5, 82
Lipper RA, 1999, Modern Drug Discovery, 2, 55
Moghimi S, 2001, Pharmacol Rev, 53, 283
Pace S, 1999, Pharm Tech, 23, 116
Peters K, 1996, In Proceeding European Symposium on Formulation of Poorly-available Drugs for Oral Administration, 330
Shah J, 2007, At 42nd Annual Technology Arden Conference—Best Practices for Parenteral Dosage Forms: Formulation, Process, Development, Package Selection and Manufacturing. AAPS Meetings and Expositions
Shott H, 1995, Remington: The Science and Practice of Pharmacy, 1, 252